COSTA MESA, CA--(Marketwired - Mar 22, 2017) - NEMUS Bioscience, Inc. (OTCQB: NMUS) and the company's discovery and research
partner, the University of Mississippi (UM), today announced that bactericidal synergy was achieved against multiple species of
methicillin-resistant Staphylococcus aureus (MRSA) utilizing a proprietary cannabinoid-based therapeutic
platform. MRSA species tested included community acquired- (CA-MRSA), healthcare-acquired- (HA-MRSA), and
mupirocin-resistant (MR-MRSA) strains of MRSA.
In vitro studies demonstrated that when using unique strategic cannabinoid-based cocktails, fractional-inhibitory
concentration (FIC) levels demonstrating synergy between mixtures of individual cannabinoid-based components ranged from 0.06 to
0.28. FIC findings below 0.5 indicate significant killing potential of the mixture.
"This work highlights the importance of Nemus' relationship with the University which has significant experience and
intellectual capital related to cannabinoid chemistry and physiology, dating back to 1968," stated Brian Murphy, M.D., C.E.O. and
Chief Medical Officer of Nemus. "These unique botanically derived components establish an anti-infective platform which
could potentially be expanded into other types of bacteria, as well as viruses, and fungi."
Dr. Mahmoud ElSohly, professor at the National Center for Natural
Products Research (NCNPR) at the University of Mississippi commented: "The University, in conjunction with Nemus, is looking
to expand the anti-infective capabilities of this series of compounds. Historically, many types of anti-infective compounds
are derived from plants so to have a series of cannabinoid-related compounds exhibit activity against this dangerous pathogen is
in keeping with prior efforts of drug development. I believe that these compounds, in addition to the bacterial killing
capability, could also offer benefits associated with anti-inflammatory and anti-fibrotic properties that could enhance healing,
especially against an organism associated with skin and soft tissue infections."
"This anti-infective platform will constitute the NB3000 series of Nemus molecules and formulations. Recently, the World
Health Organization (WHO) placed MRSA on their list as one of the top six organisms that pose a global public health threat.
While there are a number of compounds in the development pipeline against MRSA, we believe that this family of drug candidates
could possess an excellent safety profile in addition to efficacy in neutralizing this bacterium," stated Dr. Murphy. "Nemus
will work with Dr. Elsohly, the University lead researcher on this project, to have this data submitted to a future scientific
meeting and anticipates performing further testing against a variety of other bacterial species. Commercially, the company
looks to actively pursue partnering opportunities for these candidate molecules."
FORWARD LOOKING STATEMENT
This press release contains forward-looking statements, including statements about the studies relating to and the
potential benefits of the NB3000 series of drug candidates as well as the timing of our near term, intermediate term and long
term goals. Such statements and other statements in this press release that are not descriptions of historical facts are
forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and
uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results,
financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be
identified by terminology including "goal," "focus," "aims," "expects," "plans," "believes," "can," "could," "challenge,"
"predictable," "will," or the negative of these terms or other comparable terminology. We operate in a rapidly changing
environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor
can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and
uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty
regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of
NEMUS's most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by
law, NEMUS disclaims any intent or obligation to update these forward-looking statements.
ABOUT NEMUS BIOSCIENCE, INC.
The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development,
and commercialization of cannabinoid-based therapeutics for significant unmet medical needs in global markets. Utilizing certain
proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver
cannabinoid-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting
potential adverse events. NEMUS's strategy is to explore the use of natural and synthetic compounds, alone or in combination with
partners. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and
significant background in early-stage drug development.
For more information, visit http://www.nemusbioscience.com.
ABOUT THE UNIVERSITY OF MISSISSIPPI
The University of Mississippi, the state's flagship institution, is among the elite group of R-1: Doctoral
Universities - Highest Research Activity in the Carnegie Classification. The university has a long history of producing leaders
in public service, academics, research and business. Its 15 academic divisions include a major medical school, nationally
recognized schools of accountancy, law and pharmacy, and an Honors College acclaimed for a blend of academic rigor, experiential
learning and opportunities for community action.